Literature DB >> 23418847

Cancer survival and prevalence in Australia: period estimates from 1982 to 2010.

.   

Abstract

AIM: The Australian Institute of Health and Welfare (AIHW) is a major national agency established by the Australian government to provide reliable, regular and relevant information and statistics on Australia's health and welfare. The AIHW publishes updated information on survival and prevalence of cancer in Australia on a regular basis.
METHODS: The latest national survival and prevalence statistics for cancer in Australia from 1982 to 2010 are presented. The period method is used in survival calculations. Limited duration prevalence by sex and 5-year relative survival by age, sex, remoteness from major centers and socioeconomic status are examined in detail for all cancers combined as well as for selected cancers. National conditional survival statistics are also presented.
RESULTS: Five-year survival from all cancers combined increased from 47% in the period 1982-1987 to 66% in 2006-2010. Over the same period, prostate cancer, kidney cancer and non-Hodgkin's lymphoma had the largest increases in 5-year survival, while many of the cancers that already had a low survival in 1982-1987 (such as mesothelioma and pancreatic cancer) showed only small increases. For those who have already survived 5 years past their cancer diagnosis, their survival prospects for the next 5 years were more than 90% for all cancers combined. At the end of 2007 there were 774 700 Australians, or 3.6% of the population, living with a diagnosis of cancer in the previous 26 years. The prevalence was particularly high for breast cancer, melanoma of the skin, prostate cancer and bowel cancer.
© 2013 Wiley Publishing Asia Pty Ltd.

Entities:  

Mesh:

Year:  2013        PMID: 23418847     DOI: 10.1111/ajco.12062

Source DB:  PubMed          Journal:  Asia Pac J Clin Oncol        ISSN: 1743-7555            Impact factor:   2.601


  26 in total

1.  Supportive care needs and preferences of lung cancer patients: a semi-structured qualitative interview study.

Authors:  Natasha M K Brown; Chi-Wai Lui; Peter C Robinson; Frances M Boyle
Journal:  Support Care Cancer       Date:  2014-11-14       Impact factor: 3.603

2.  The continual search for ideal biomarkers for mesothelioma: the hurdles.

Authors:  Fraser J Brims; Y C Gary Lee; Jenette Creaney
Journal:  J Thorac Dis       Date:  2013-06       Impact factor: 2.895

3.  Chemotherapy-induced hypomethylation of N-myc downstream-regulated gene 4 in the bone marrow of patients with acute myeloid leukemia.

Authors:  Qingxiao Hong; Xiaoying Chen; Huadan Ye; Xiaodong Wu; Xuejing Wang; Lingyan Kong; Yongming Xia; Shiwei Duan
Journal:  Oncol Lett       Date:  2017-03-10       Impact factor: 2.967

Review 4.  Epidemiology of renal cancer in developing countries: Review of the literature.

Authors:  Mauricio Medina-Rico; Hugo López Ramos; Manuel Lobo; Jorge Romo; Juan Guillermo Prada
Journal:  Can Urol Assoc J       Date:  2017-12-22       Impact factor: 1.862

5.  Successful use of central venous catheters in the management of recurrent malignant pleural effusions: one new option.

Authors:  Abbas Yazdanbod; Azita Salehifar; Nasrollah Maleki; Shahram Habibzadeh; Zahra Tavosi
Journal:  Support Care Cancer       Date:  2015-01-10       Impact factor: 3.603

6.  Crude probability of death for cancer patients by spread of disease in New South Wales, Australia 1985 to 2014.

Authors:  Xue Qin Yu; Paramita Dasgupta; Clare Kahn; Kou Kou; Susanna Cramb; Peter Baade
Journal:  Cancer Med       Date:  2021-05-06       Impact factor: 4.452

Review 7.  Exercise for reducing falls in people living with and beyond cancer.

Authors:  Andrew D Williams; Marie-Louise Bird; Sibella Gk Hardcastle; Mark Kirschbaum; Kathryn J Ogden; Julia Ae Walters
Journal:  Cochrane Database Syst Rev       Date:  2018-10-15

8.  Prognostic survival model for people diagnosed with invasive cutaneous melanoma.

Authors:  Peter D Baade; Patrick Royston; Philipa H Youl; Martin A Weinstock; Alan Geller; Joanne F Aitken
Journal:  BMC Cancer       Date:  2015-01-31       Impact factor: 4.430

9.  BCG+MMC trial: adding mitomycin C to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: a randomised phase III trial (ANZUP 1301).

Authors:  Dickon Hayne; Martin Stockler; Steve P McCombie; Venu Chalasani; Anne Long; Andrew Martin; Shomik Sengupta; Ian D Davis
Journal:  BMC Cancer       Date:  2015-05-27       Impact factor: 4.430

10.  Cancer risks for relatives of children with cancer.

Authors:  John A Heath; Elizabeth Smibert; Elizabeth M Algar; Gillian S Dite; John L Hopper
Journal:  J Cancer Epidemiol       Date:  2014-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.